Show simple item record

dc.contributor.authorSanyal, Sen
dc.contributor.authorChild, Fen
dc.contributor.authorAlfred, Aen
dc.contributor.authorCallaghan, Ten
dc.contributor.authorAlband, Nen
dc.contributor.authorWhittaker, Sen
dc.contributor.authorWain, Men
dc.contributor.authorMorris, Sen
dc.contributor.authorMalladi, Ren
dc.contributor.authorCowan, Richard Aen
dc.contributor.authorParry, Eileenen
dc.contributor.authorRobinson, Sen
dc.contributor.authorHowles, Aen
dc.contributor.authorDunnill, Men
dc.contributor.authorTahir, Sen
dc.contributor.authorArumainathan, Aen
dc.contributor.authorAzurdia, Ren
dc.contributor.authorMatin, R Nen
dc.contributor.authorGilson, Den
dc.contributor.authorGrant-Casey, Jen
dc.contributor.authorHowell, Cen
dc.contributor.authorEl-Ghariani, Ken
dc.contributor.authorTaylor, Pen
dc.contributor.authorScarisbrick, Jen
dc.date.accessioned2017-09-08T11:29:53Z
dc.date.available2017-09-08T11:29:53Z
dc.date.issued2017-08-07
dc.identifier.citationUK national audit of extracorporeal photopheresis in CTCL. 2017 Br J Dermatolen
dc.identifier.issn1365-2133
dc.identifier.pmid28782100
dc.identifier.doi10.1111/bjd.15871
dc.identifier.urihttp://hdl.handle.net/10541/620546
dc.descriptionLymphoma Research Teamen
dc.description.abstractWe performed a national audit of extracorporeal photopheresis (ECP) in cutaneous T-cell lymphoma (CTCL) to gather information on number of treatment cycles, treatment duration and reason for stopping. UK Consensus Guidelines and European ECP Guidelines recommend that ECP can be considered for first-line treatment for erythrodermic CTCL patients with blood involvement [1,2,3]. Publications have shown effectiveness of ECP in early-stage MF, stage IA-IIA [4,5] and ECP is listed as a systemic treatment option in refractory early-stage MF in the National Comprehensive Cancer Network Guidelines [6]. This article is protected by copyright. All rights reserved.
dc.language.isoenen
dc.rightsArchived with thanks to The British journal of dermatologyen
dc.titleUK national audit of extracorporeal photopheresis in CTCL.en
dc.typeArticleen
dc.contributor.departmentUniversity Hospital Birmingham, Birmingham, UKGuy's & St Thomas' NHS Trust, Londonen
dc.identifier.journalThe British Journal of Dermatologyen
html.description.abstractWe performed a national audit of extracorporeal photopheresis (ECP) in cutaneous T-cell lymphoma (CTCL) to gather information on number of treatment cycles, treatment duration and reason for stopping. UK Consensus Guidelines and European ECP Guidelines recommend that ECP can be considered for first-line treatment for erythrodermic CTCL patients with blood involvement [1,2,3]. Publications have shown effectiveness of ECP in early-stage MF, stage IA-IIA [4,5] and ECP is listed as a systemic treatment option in refractory early-stage MF in the National Comprehensive Cancer Network Guidelines [6]. This article is protected by copyright. All rights reserved.


This item appears in the following Collection(s)

Show simple item record